Mechanisms of Clozapine-Induced Agranulocytosis

Stanton L. Gerson*, Herbert Meltzer

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

98 Scopus citations

Abstract

The aetiology of clozapine-induced agranulocytosis remains unknown. Leading candidates include an immune mechanism that is possibly complement- or drug-dependent and a toxic mechanism. We analysed these mechanisms by culturing the granulocyte precursor stem cell from the bone marrow in the presence of patients’ serum, clozapine or clozapine metabolites. Studies with patients’ serum failed to identify an immune mechanism. On the basis of our preliminary data, it appears that a toxic mechanism may be responsible, and this is more likely to be due to a metabolite than to clozapine itself Further studies are required to determine the sensitivity of bone marrow precursors to these clozapine derivatives. For instance, prospective collection of serum will make it possible to evaluate whether high metabolite concentrations develop in sensitive individuals and whether they are responsible for agranulocytosis. If such elevated levels occur, further studies will be required to determine whether prospective monitoring will effectively identify patients at risk and ultimately prevent the onset of agranulocytosis by early discontinuation of the drug.

Original languageEnglish (US)
Pages (from-to)17-25
Number of pages9
JournalDrug Safety
Volume7
Issue number1
DOIs
StatePublished - Dec 1992

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Mechanisms of Clozapine-Induced Agranulocytosis'. Together they form a unique fingerprint.

Cite this